Myocardial Perfusion Magnetic Resonance Imaging Using Regadenoson
Feasibility of Detecting Myocardial Ischemia by First-pass Contrast MRI Using Regadenoson
Sponsor: Astellas Pharma US, Inc.
A EARLY_PHASE1 clinical study on Ischemic Heart Disease, this trial is completed. The trial is conducted by Astellas Pharma US, Inc. and has accumulated 7 data snapshots since 2009. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Completed EARLY_PHASE1
-
Sep 2024 — Sep 2025 [monthly]
Completed EARLY_PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed EARLY_PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed EARLY_PHASE1
-
Jun 2018 — Jan 2021 [monthly]
Completed EARLY_PHASE1
▶ Show 2 earlier versions
-
Feb 2017 — Jun 2018 [monthly]
Completed EARLY_PHASE1
Phase: Phase 0 → EARLY_PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Completed Phase 0
First recorded
Jun 2009
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Astellas Pharma US, Inc.
- Washington University School of Medicine
For direct contact, visit the study record on ClinicalTrials.gov .